Uma i-cholesterol ibe yinkinga kuwe, kungenzeka ukuthi udokotela wakho ukhulume ngoZetia (ezetimibe) noma i-Vytorin (ezetimibe plus simvastatin). I-Vytorin yasungulwa njengenhlanganisela yeZetia neZocor (simvastatin), eyayihloselwe ukuthuthukisa izakhiwo ze-cholesterol zikaZocor.
Ukudideka? Khumbula nje ukuthi iZocor yisimiso esilula - uhlobo lwezidakamizwa olusebenza esibindi ukuvimbela i-cholesterol ukuthi ingafaki.
I-Zetia yisidakamizwa esisha, esenzelwe ukuvimbela ukumuncwa kwe-cholesterol ekudleni emathunjini. I-Vytorin inhlanganisela kokubili uZocor noZetia.
UVivtorin wethulwa emphakathini ngo-2004 ngokusebenzisa izikhangiso ze-TV ezathi i-Vytorin ingalwela imithombo emibili ye-cholesterol: ukudla kanye nezakhi zofuzo. U-Vytorin wajoyina imithi eminingi ye-cholesterol eyayisivele iyatholakala emakethe, kodwa ngenani eliphansi kakhulu. Kodwa-ke, ukumaketha okukhulu kukaZetia, kamuva kuthiwa nguVittorin, washesha ngokushesha ukukhipha imithi ye-cholesterol yase-US yale mithi.
Izivivinyo Zomtholampilo Zineziphumo Ezixubile Ze Zetia no-Vytorin
U-Zetia noVivtorin baqale bavunyelwa yi-FDA ngo-2002 no-2004, ngokulandelana, ngokukwazi kwabo ukwehlisa "i-cholesterol embi" ( LDL ). I-"cholesterol embi" ikholakala ukuthi iyabangela ukufakwa kwekhabethe ezindongeni zokugcoba ezingabangela ukushaywa noma isifo senhliziyo.
NgoJanuwari 2008 , i-Merck / Schering Plow Pharmaceuticals - umenzi wobabili uZetia noVytorin - yakhipha imiphumela yocwaningo ngemiphumela yokuhlanganiswa kwe-ezetimibe kanye ne-high-dose simvastatin ngokumelene ne-simvastatin yedwa ohlelweni lwe- atherosclerotic kwiziguli ezine-heterozygous i-hypercholesterolemia yomndeni , ebizwa ngokuthi isifundo se-ENHANCE.
Lolu cwaningo lwaqhathanisa iziguli ezingu-720 ezithatha i-Vytorin noma i-Zocor kuphela. Ngokusebenzisa i-ultrasound ukuhlola ukuqhutshwa kwentamo yalezi ziguli ezivela kumabili amaqembu, abacwaningi babe nethemba lokunquma ukuthi ngabe umuthi wokuhlanganiswa, uVittorin, wehlise izigameko zokwakhiwa kwamapayipi emithanjeni yabo.
Kwakulindeleke ukuthi labo abathatha iVitotorin baboniswe ukuthi babe ne-plaque encane ezindongeni zabo zokubamba kunelabo abathatha uZocor bodwa.
Esikhundleni salokho, iziphetho zocwaningo zabonisa ukuthi iziguli zikaVivtorin zazingenalo uphawu oluncane emithanjeni yabo kunelabo abathatha iZocor kuphela. Eqinisweni, labo ababethatha uVittorin empeleni babe ne-plaque eminye.
Izindaba Ezinhle Esifundweni Sesibili
Isifundo sesibili, esibizwa ngokuthi Ukunciphisa Imiphumela Ephuthumayo: Uhlolo lwe-Vytorin Efficacy International (IMPROVE-IT), imiphumela elinganiselwe ezigulini ezingaphezu kuka-18,000 ezazikade zine-heart attack. Imiphumela yalolu cwaningo, eyabika ngo-2014, ithole iziguli ezingaphezulu kakhulu kwi-Vytorin ezetimibe / isimiso se-simvastatin zihlangene nezinhloso zazo zombili i-LDL-C ne-hs-CRP kunezo ze-simvastatin kuphela. Babenemiphumela engcono yempilo uma behlangene zombili izinhloso, njengoba kulinganiswa ukufa komzimba, umcimbi omkhulu we-coronary, noma isifo sohlangothi. Ingozi yabo yokuphindaphinda inhliziyo noma ukushaya isifo yanciphisa ngo-6%. Ukwelashwa okuhlangene akubonanga imiphumela emibi kakhulu, ikakhulukazi engozini yomdlavuza.
Lokhu kwaqhubeka nokuphikisana - kuwukufanelekela ukuthatha isidakamizwa esenza ama-lab wakho akho abukeke kangcono, kodwa unokuthuthukiswa okuncane kwemiphumela yakho yempilo, uma ikhona?
I-Vytorin yayinezixwayiso nezinyathelo zokuqapha ezongezwe ngo-2010 futhi zivuselelwe njalo ukuthi izixwayiso zengozi enkulu yokumama / i-rhabdomyolysis. Lokhu kufaka phakathi izixwayiso zalokhu ekuhlanganyeleni ne-niacin ne-fibrates.
Ingabe Kufanele Ngiyeke Ukuthatha iZetia noma i-Vytorin?
Akunjalo ngokushesha. I-plaque ye-arterial eceleni, iziguli zaseVittorin zenza kahle kakhulu kwesinye isilinganiso, okungukuthi, amazinga aphansi we "cholesterol embi," okuwumphumela ofanayo owawuthola imvume ye-FDA kuqala. Uma kuqhathaniswa neziguli zeZocor, iziguli zeVittorin zathola ukwehla okuphawulekayo emazingeni "ama-cholesterol amabi". Ukuthi kungani iziguli zikaVittorin ekucwaningweni zazinamazinga aphansi okuthiwa "ama-cholesterol" angenakho ukuthuthukiswa kwe-plaque yokufakelwa engakaqondakali. I-FDA iyaqhubeka nokuphenya lobufakazi.
Ngokuqondene noZetia, izifundo zangaphambilini zibonise ukuthi le mithi ibuye ithinte amazinga aphansi okuthiwa "ama-cholesterol".
Ngisho noma kungahlanganiswa neZocor, labo ababeletha u-Zetia babonakala benemiphumela eyayivimbela ukumuncwa kwe-cholesterol ekudleni okudlula emathunjini.
I-American Heart Association iye yazindla ngalolu daba ngokucebisa iziguli ezithatha uVytorin ukuba angashiyi ukwelashwa ngenxa yengozi yokwanda kwezempilo engcupheni yokuqeda ngokushesha ukwelashwa kwe-cholesterol. Ngisho nokushintshela komunye umuthi kungenzeka ukuthi akudingekile ngezizathu eziningana:
- Ngisho neziphumo ezidumazayo ekutadisheni kokuqala, uVivtorin akazange aboniswe ukuthi akaphephile.
- I-statin equkethe iVivtorin inezinzuzo ezisekelwe isikhathi eside zokulwa ne-cholesterol.
- I-Vytorin noma i-Zetia kungenzeka ibekiwe kwabanye iziguli ngoba iZocor noma enye i-statin yedwa ayiphumelelanga ekunciphiseni "i-cholesterol yabo embi."
- Imithi engafanele ingase ingakeluleki kwezinye iziguli, ngenxa yezimo zezokwelapha ezingahlobene.
Okufanele ngikwenze
Njengoba njalo, kufanele uhlole nodokotela wakho. Buza ukuthi kunezimo okufanele zikugcine kulokho okwelashwa manje noma uma kufanele uqale ukuhlola ezinye izindlela.
Uma udokotela wakho eluleka ukuthi uhlala efundeni neVivinin noma i-Zetia, kufanele:
- Qhubeka ulandela izinguquko zokuphila zokunconywa zokudla , ukuzivocavoca nokugwema ukubhema ukugcina ikholesterol yakho isheke.
- Gcina ama-aphoyintimenti akho futhi uqaphele noma yikuphi ushintsho kuphaneli yakho ye- lipid ukuze unqume ukuthi ngabe ukwelapha kwakho kwezidakamizwa kusebenza njengoba kulindeleke.
- Gada izimpawu zakho zansuku zonke futhi ubike noma yimiphi imiphumela emibi ongase ubhekene nodokotela wakho.
Nazi ezinye izimo ezimbi ezingase zibe khona ukuze ubuke ngenkathi uthatha iVytorin:
- ikhanda
- ubuhlungu bomzimba noma ubuhlungu
- ukusabela okweqile, kubandakanya ukuqhuma noma ukuvuvukala
- izimpawu zesibindi noma ukuvuvukala kwe-gallbladder, kufaka phakathi ubuhlungu obukhulu besisu kanye nomchamo ongavamile wemigodi nezihlalo
I-FDA iqhubeka nokuhlola ukufundwa kwezifundo ukuze kutholakale ukuthi yisiphi isenzo esiqinisekisiwe. Uma ukholelwa ukuthi uye wabhekana nemiphumela emibi, noma uma uhlangabezane nesenzakalo esibi njengesihlasela senhliziyo noma isifo sohlangothi, ngenkathi uthatha iVytorin noma i-Zetia, ucelwa ukuba uyibike ohlelweni lwe-MedWatch Adverse Event Reporting ku-FDA.
Imithombo:
Abasebenzi base-American Heart Association. "Ukwelashwa Kwezidakamizwa Nge-Cholesterol." I-AmericanHeart.org . 4/21/2014. I-American Heart Association. Ngo-February 11, 2016.
Abasebenzi base-American Heart Association. "Isitatimende esivela ku-American Heart Association ku-ENHANCE ukutadisha imiphumela." I-AmericanHeart.org . 15 Jan. 2008. American Heart Association. 29 Mashi 2008
UJackevicius, uCynthia. "Ukusetshenziswa kwe-Ezetimibe e-United States naseCanada." I-New England Journal of Medicine . 28 Mashi 2008. I-New England Journal of Medicine. 3 Meyi 2008.
Abasebenzi bakwa-US Food Administration and Drug Administration, "Ukukhulumisana Kwangaphambili mayelana nokubuyekezwa kwedatha okuqhubekayo e-Ezetimibe / Simvastatin (okudayiswa njengeVitoin), i-Ezetimibe (okudayiswa njengeZetia), kanye neSimvastatin (edayiswa njengeZocor)." FDA.gov . 25 Jan. 2008. Ukuphathwa Kwezokudla Nezidakamizwa zase-US. 29 Mashi 2008.
Abasebenzi bakwa-US Food Administration and Drug Administration, "Ngaphakathi Izivivinyo Zomtholampilo: Imikhiqizo Yezokwelapha Zokuhlola Abantu." FDA.gov . 1 Sep. 2003. US Ukuphathwa Kwezokudla Nezidakamizwa. 3 Meyi 2008
Abasebenzi base-US Food Administration and Drug Administration, "i-Vytorin (ezetimibe / simvastatin) tablet." FDA.gov . Februwari 2014. Ukuphathwa Kwezokudla Nezidakamizwa zase-US. Ngo-February 11, 2016.
Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, i-White JA, i-Tershakovec AM, i-Blazing MA, i-Braunwald E. Ukuphumelela kwe-double-volensity ye-lipoprotein cholesterol nokuzwela okukhulu. i-ezetimibe kuya kwi-simvastatin futhi ihlotshaniswa nemiphumela engcono ku-IMPROVE-IT. Ukujikeleza. 2015 Sep 29; 132 (13): 1224-33. i-doi: 10.1161 / i-CIRCULATIONAHA.115.018381. I-Epub 2015 Sep 1.
ULancellotti P, Pierard LA, Scheen AJ. [I-ACUTE CORONARY SYNDROME NE-LIPID-LOWERING THERAPY. INGABE UKUTHUTHA-UKUFUNDA KWAKHO KUPHELA KANYE NOKUPHAKATHI?]. [Isihloko sesiFulentshi] Rev Med Liege. 2015 Sep; 70 (9): 450-5.